 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Meridian Bioscience, Inc. (VIVO) develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. 
The company operates through Diagnostics and Life Science segments.
The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood.
It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.
The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications.
On May 6th, Meridian reported 2nd Quarter March 2022 earnings of $0.66 per share on revenue of $111.2 million. The consensus earnings estimate was $0.48 per share on revenue of $99.5 million. Revenue grew 30.5% on a year-over-year basis.
The company said it expects fiscal 2022 earnings of $1.30 to $1.40 per share on revenue of $330.0 million to $345.0 million. The company's previous guidance was earnings of $1.10 to $1.30 per share on revenue of $315.0 million to $330.0 million.
Shares are heading higher in an upward trading channel. Presently shares are at the lower boundary of the channel.
Entry Point: $26.00
Trading Range: $17.04 to $29.00
Stop Loss: $23.50
Target Price: $29.00
